Cargando…

A Novel Immune-Related Gene Prognostic Index (IRGPI) in Pancreatic Adenocarcinoma (PAAD) and Its Implications in the Tumor Microenvironment

SIMPLE SUMMARY: Pancreatic adenocarcinoma (PAAD) is one of the leading causes of cancer death across the world, with extremely poor clinical outcomes within 5 years. From that end, survival prediction for such patients is essential, while in-service biomarkers are in need to be improved. Therefore,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Shujing, Szöllősi, Attila Gábor, Huang, Xufeng, Chang-Chien, Yi-Che, Hajdu, András
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688924/
https://www.ncbi.nlm.nih.gov/pubmed/36428747
http://dx.doi.org/10.3390/cancers14225652
Descripción
Sumario:SIMPLE SUMMARY: Pancreatic adenocarcinoma (PAAD) is one of the leading causes of cancer death across the world, with extremely poor clinical outcomes within 5 years. From that end, survival prediction for such patients is essential, while in-service biomarkers are in need to be improved. Therefore, in the present study, we developed a machine learning-based prognostic model for robust and accurate survival prediction for PAAD patients. Additionally, we explored its critical implications in the tumor immunological microenvironment, sharing new insights into new therapeutic strategies in the future. ABSTRACT: Purpose: Pancreatic adenocarcinoma (PAAD) is one of the most lethal malignancies, with less than 10% of patients surviving more than 5 years. Existing biomarkers for reliable survival rate prediction need to be enhanced. As a result, the objective of this study was to create a novel immune-related gene prognostic index (IRGPI) for estimating overall survival (OS) and to analyze the molecular subtypes based on this index. Materials and procedures: RNA sequencing and clinical data were retrieved from publicly available sources and analyzed using several R software packages. A unique IRGPI and optimum risk model were developed using a machine learning algorithm. The prediction capability of our model was then compared to that of previously proposed models. A correlation study was also conducted between the immunological tumor microenvironment, risk groups, and IRGPI genes. Furthermore, we classified PAAD into different molecular subtypes based on the expression of IRGPI genes and investigated their features in tumor immunology using the K-means clustering technique. Results: A 12-gene IRGPI (FYN, MET, LRSAM1, PSPN, ERAP2, S100A1, IL20RB, MAP3K14, SEMA6C, PRKCG, CXCL11, and GH1) was established, and verified along with a risk model. OS prediction by our model outperformed previous gene signatures. According to the findings of our correlation studies, different risk groups and IRGPI genes were found to be tightly related to tumor microenvironments, and PAAD could be further subdivided into immunologically distinct molecular subtypes based on the expression of IRGPI genes. Conclusion: The current study constructed and verified a unique IRGPI. Furthermore, our findings revealed a connection between the IRGPI and the immunological microenvironment of tumors. PAAD was differentiated into several molecular subtypes that might react differently to immunotherapy. These findings could provide new insights for precision and translational medicine for more innovative immunotherapy strategies.